UBC Insights

Insights from
UBC's Expert Voices

Featured Updates

Featured Image
Blog
6 min read

Summary and Key Takeaways from FDA’s September 2026 Public Hearing on Psychedelic Drugs

On September 14, 2026, FDA convened a Part 15 hearing to discuss "Considerations for Potential Future Therapeutic Use of Psychedelic Drugs." The meeting was a compilation of 2 minute segments for 80 public commentators representing a diverse community of academia, patients, advocates, service providers, and industry.
Rachel Bonfanti, MPH
Executive Director, Risk Management & Scientific Consulting

Posts by Date

office colleagues collaborating on computer
Blog
7 min read

Navigating 2026: Patient service themes, challenges, and solutions

As we look ahead to 2026, patient access and support services face growing complexity—from affordability challenges and evolving care models to the rise of specialty therapies. This blog explores the key trends shaping the healthcare landscape and offers strategic solutions, including AI-powered innovation, digital transformation, and partnerships that drive better outcomes. Discover how UBC is leading the way with patient-first strategies to simplify the patient and product journey.
Dana Edwards
Vice President, Patient Access & Strategic Engagement
artificial intelligence
Blog
18 min read

Navigating the AI Landscape: Choosing the Right Model for Your PV Needs

AI is no longer just a buzzword—it’s a practical tool shaping how we work every day. Learn how UBC leverages AI models to streamline tasks, enhance decision-making, and maintain compliance.
Abstract image of iridescent translucent bubbles floating against a black background, reflecting blue, purple, and rainbow light.
Blog
2 min read

Redefining Real-World Data: How Datavant Scales Medical Record Retrieval for Complete, Connected Insights

Modern medical record retrieval is transforming real-world evidence. Datavant’s approach combines nationwide reach, deep data connectivity, and high record yields to deliver comprehensive, research-ready datasets.
From Voices to Breakthrough: Breakthrough Summit
Blog
7 min read

2025 NORD Rare Disease Summit: Advancing Evidence and Partnerships for the Rare Community

UBC attended the 2025 NORD Rare Diseases & Orphan Products Breakthrough Summit, where patient voices, scientific innovation, and regulatory expertise converged to shape the future of rare-disease research. Learn what inspired us and how we’re advancing real-world evidence, patient partnerships, and innovative trial designs to accelerate progress for the rare-disease community.
Julie Shutt
Associate Director, Patient Engagement
cell and gene, dna
Blog
5 min read

High-Touch, High-Impact: Optimizing Patient Support in Cell & Gene Therapy

As cell and gene therapies reshape treatment paradigms, patient support programs must evolve to meet new challenges. Discover how strategic alignment, payer advocacy, and innovative solutions can optimize the patient journey.
Dana Edwards
Vice President, Patient Access & Strategic Engagement
lightbulb in center
Blog
6 min read

Registry feasibility assessments for post-authorization safety studies (PASS): Learnings and Challenges

UBC recently completed a multi-country feasibility assessment to identify disease registries capable of supporting a PASS for a novel therapy targeting a hereditary muscular disorder. The study evaluated registry data elements, quality, and governance to ensure fit-for-purpose real-world data (RWD) for generating reliable RWE.
person analyzing data on laptop, focusing on various charts and graphs displayed on screen. setting suggests modern workspace, emphasizing productivity and technology.
Blog
9 min read

Making the most of real-time pharmacovigilance oversight: Applying operational data analytics across diverse use cases

Learn how companies are making the most of their oversight capabilities by leveraging real-time data to improve the health of their pharmacovigilance program.
Blue abstract background with light traveling through abstract flat cable illustrating data flow (3D render)
Blog
20 min read

Putting a Seatbelt on AI: How Risk-Based Integration is Transforming Drug Safety

AI is revolutionizing drug safety, but without proper guardrails, it can introduce new risks. Learn how risk-based integration strategies are helping life sciences companies harness AI’s power while maintaining trust, transparency, and compliance.
Marios Abatis
Safety Scientist, Global Case Processing Team
The data analyst woman working on a business analytics dashboard, utilizing charts and metrics to analyze performance and generate insightful reports for operations management
Blog
12 min read

Operational Data On Demand: Overcoming Barriers to Effective Pharmacovigilance Oversight

Platforms designed specifically for the collection and communication of operational pharmacovigilance data are breaking down long-standing barriers to real-time PV oversight.
1 2 3 4 5 6 21

Press Inquires

UBC logo white

Thank You for Connecting with UBC

.

 

What You Can Expect Next

.

UBC logo white

Get Ready to Change Your Business

.

Service Request

Bekki Bracken Brown Headshot

Bekki Bracken Brown

President & Chief Executive Officer

Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.

With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.